Student and Faculty Publications
Publication Date
3-6-2023
Journal
Journal of Experimental Medicine
Abstract
Immunotherapy has greatly improved cancer outcomes, yet variability in response and off-target tissue damage can occur with these treatments, including immune checkpoint inhibitors (ICIs). Multiple lines of evidence indicate the host microbiome influences ICI response and risk of immune-related adverse events (irAEs). As the microbiome is modifiable, these advances indicate the potential to manipulate microbiome components to increase ICI success. We discuss microbiome features associated with ICI response, with focus on bacterial taxa and potential immune mechanisms involved in irAEs, and the overall goal of driving novel approaches to manipulate the microbiome to improve ICI efficacy while avoiding irAE risk.
Keywords
Humans, Antineoplastic Agents, Immunological, Neoplasms, Microbiota, Immunotherapy, Retrospective Studies
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Microbiology Commons, Medical Toxicology Commons, Oncology Commons
Comments
PMID: 36622383